Perrigo Company plc APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
Perrigo Company plc (PRGO) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $6.80 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2026-08-05
- Perrigo Company plc apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2026-06-27 was $6.80M, a 59.52% decline year-over-year.
- Perrigo Company plc apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2026-03-28 was $14.40M, a 24.14% increase year-over-year.
- Perrigo Company plc apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-09-27 was $13.90M, a 16.27% decline year-over-year.
- Perrigo Company plc apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-06-28 was $16.80M, a 28.21% decline year-over-year.
- Perrigo Company plc apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2025 was $55.20M, a 14.29% decline from fiscal 2024.
- Perrigo Company plc apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2024 was $64.40M, a 6.40% decline from fiscal 2023.
- Perrigo Company plc apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2023 was $68.80M, a 25.32% increase from fiscal 2022.
- Perrigo Company plc apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2022 was $54.90M, a 17.94% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-27 | $6.80M 10-Q · filed 2026-08-05 | $21.20M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2026-03-28 | $14.40M 10-Q · filed 2026-08-05 | ||||
| 2025-12-31 | $55.20M 10-K · filed 2026-02-26 | ||||
| 2025-09-27 | $13.90M 10-Q · filed 2025-11-05 | $30.70M derived: sum of 2 quarters · filed 2026-08-05 | $42.30M derived: sum of 3 quarters · filed 2026-08-05 | ||
| 2025-06-28 | $16.80M 10-Q · filed 2026-08-05 | $28.40M derived: sum of 2 quarters · filed 2026-08-05 | |||
| 2025-03-29 | $11.60M 10-Q · filed 2026-08-05 | ||||
| 2024-12-31 | $64.40M 10-K · filed 2026-02-26 | ||||
| 2024-09-28 | $16.60M 10-Q · filed 2025-11-05 | $40.00M derived: sum of 2 quarters · filed 2025-11-05 | $55.60M derived: sum of 3 quarters · filed 2025-11-05 | ||
| 2024-06-29 | $23.40M 10-Q · filed 2025-11-05 | $39.00M derived: sum of 2 quarters · filed 2025-11-05 | |||
| 2024-03-30 | $15.60M 10-Q · filed 2025-11-05 | ||||
| 2023-12-31 | $68.80M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $14.70M 10-Q · filed 2024-11-06 | $33.30M derived: sum of 2 quarters · filed 2024-11-06 | $58.20M derived: sum of 3 quarters · filed 2024-11-06 | ||
| 2023-07-01 | $18.60M 10-Q · filed 2024-11-06 | $43.50M derived: sum of 2 quarters · filed 2024-11-06 | |||
| 2023-04-01 | $24.90M 10-Q · filed 2024-11-06 | ||||
| 2022-12-31 | $54.90M 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | $9.30M 10-Q · filed 2023-11-07 | $18.30M derived: sum of 2 quarters · filed 2023-11-07 | $44.60M derived: sum of 3 quarters · filed 2023-11-07 | ||
| 2022-07-02 | $9.00M 10-Q · filed 2023-11-07 | $35.30M derived: sum of 2 quarters · filed 2023-11-07 | |||
| 2022-04-02 | $26.30M 10-Q · filed 2023-11-07 | ||||
| 2021-12-31 | $66.90M 10-K · filed 2024-02-27 | ||||
| 2021-10-02 | $18.50M 10-Q · filed 2022-11-08 | $32.40M derived: sum of 2 quarters · filed 2022-11-08 | $57.00M derived: sum of 3 quarters · filed 2022-11-08 | ||
| 2021-07-03 | $13.90M 10-Q · filed 2022-11-08 | $38.50M derived: sum of 2 quarters · filed 2022-11-08 | |||
| 2021-04-03 | $24.60M 10-Q · filed 2022-11-08 | ||||
| 2020-12-31 | $56.50M 10-K · filed 2023-02-28 | ||||
| 2020-09-26 | $13.80M 10-Q · filed 2021-11-12 | $26.90M derived: sum of 2 quarters · filed 2021-11-12 | $42.30M derived: sum of 3 quarters · filed 2021-11-12 | ||
| 2020-06-27 | $13.10M 10-Q · filed 2021-11-12 | $28.50M derived: sum of 2 quarters · filed 2021-11-12 | |||
| 2020-03-28 | $15.40M 10-Q · filed 2021-11-12 | ||||
| 2019-12-31 | $50.60M 10-K · filed 2022-03-01 | ||||
| 2019-09-28 | $11.90M 10-Q · filed 2020-11-05 | $26.10M derived: sum of 2 quarters · filed 2020-11-05 | $40.30M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-29 | $14.20M 10-Q · filed 2020-11-05 | $28.40M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-30 | $14.20M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $29.60M 10-K · filed 2021-03-01 | ||||
| 2018-09-29 | $3.80M 10-Q · filed 2019-11-06 | $10.70M derived: sum of 2 quarters · filed 2019-11-06 | $20.70M derived: sum of 3 quarters · filed 2019-11-06 | ||
| 2018-06-30 | $6.90M 10-Q · filed 2019-11-06 | $16.90M derived: sum of 2 quarters · filed 2019-11-06 | |||
| 2018-03-31 | $10.00M 10-Q · filed 2019-11-06 | ||||
| 2017-12-31 | $34.90M 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $18.00M 10-K · filed 2019-02-27 | ||||
| 2015-12-31 | $20.30M 10-K · filed 2018-03-01 | $22.30M 10-KT · filed 2016-02-25 | |||
| 2015-06-27 | $24.70M 10-K · filed 2018-03-01 | ||||
| 2014-06-28 | $18.10M 10-K · filed 2017-05-22 | ||||
| 2013-06-29 | $12.30M 10-KT · filed 2016-02-25 | ||||
| 2012-06-30 | $14.00M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |